NEO: Bull Flag detected on 3 Sep 2026

NEO is forming a bull flag on strong three-month momentum (+71.6%). The structure scores 15.0/15, indicating a well-defined pattern. The stock is consolidating between resistance at 16.45 and support at 15.48, currently at 17.40. Breakout quality is solid with a 11.6/13 score. Volume shows neutral participation (1.04 ratio), and the pattern delivers a 76.41% win probability—a compelling risk-reward setup. RSI sits neutral at 58.63, showing no overbought extremes that would invalidate the setup.

NEO reported 11% YoY revenue growth to $201.7M in Q2 2026, with clinical revenue up 14% driven by 12% AUP growth and 2% volume increase. NGS revenue surged 26%. Management raised full-year 2026 EBITDA guidance to $56-58M and raised revenue guidance. NEO launched an FDA-approved PTEN IHC companion diagnostic for prostate cancer in July 2026. The RaDaR ST MRD assay targets a $20B underpenetrated addressable market. Positive earnings surprises and product launches are fueling momentum, while Health Care sector regime remains bullish (+0.57), supporting the bull flag formation.

A successful breakout above 16.45 resistance would target 17.97 conservatively, representing a +9% measured move from breakout point. Volume confirmation is critical—historical bull flags require above-average volume to validate the breakout (current 1.04x ratio adequate but not exceptional). The pattern invalidates below support at 15.48, which would breach the flag's lower boundary. With 76.41% win probability, the risk-reward suggests two units of reward for each unit of risk, favoring long-side traders. Time and price confluence matter; the flag should resolve within the next 2-4 weeks.

NEO faces increased interest expenses from a 50 basis point rate rise on new convertible notes. GuruFocus detected 3 warning signs on NEO. While no imminent earnings date exists (Q3 typically reports in October), macro headwinds persist—broader market regime is bearish (-0.23), creating potential sector rotation risk despite Health Care strength. Beta is low (0.64), reducing downside velocity, but volatility at 49% elevation requires tight stop discipline. NGS deceleration risk exists if growth moderates from 26% levels. Institutional sentiment and capital allocation decisions on the $275M convertible notes could suppress upside if dilution concerns emerge.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.